CSF3 and plasma cell myeloma: Motixafortide was recently approved by the FDA in September 2023 [109] based on evidence from the GENESIS study, a double-blind, placebo-controlled prospective randomized study in which 122 participants with multiple myeloma undergoing autologous transplantation were randomized 2:1 to receive motixafortide 1.25 mg/kg with G-CSF or a placebo with G-CSF for mobilization of HSPCs for collection and apheresis [110].